KiOmed Pharma secures €18 Million to accelerate development of innovative medical solutions - BioWin
Summary
KiOmed Pharma secured €18 million to accelerate the development and expansion of its medical solutions. The company will use the funding to grow KiOmedine, its treatment for knee osteoarthritis, and to advance work in aesthetic medicine and ophthalmology. KiOmed Pharma already markets the product in more than ten European countries and the Middle East, and it is preparing to enter additional regions, including China. The company also highlighted strategic partnerships with Hansoh Pharmaceutical and Sinclair to support its international rollout and pipeline development.
Funding
Amount
$19.5M
Total raised
Date
March 31, 2025
Announcement date
Investors
Sinclair Pharma
Lead investors
Company
kiomedpharma.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected